Need for Prompt Epinephrine Use in Anaphylaxis
A panelist discusses how anaphylaxis should be defined and treated promptly with epinephrine, highlighting the concerning statistic that not all patients who experience anaphylaxis receive this critical first-line treatment.
Video content above is prompted by the following:
Amar Dixit, MD, MBA, FACAAI, FAAAI, a board-certified allergist and immunologist, opens the presentation "Beyond the Needle: Promoting Prompt Anaphylaxis Treatment." He outlines key objectives: discussing timely epinephrine administration, identifying challenges with epinephrine use, applying strategies for patient education, and exploring intranasal epinephrine's potential. A polling question reveals 60% of attendees frequently encounter patients at risk of Type 1 allergic reactions, confirming the topic's relevance to their practices.
Dr. Dixit explains the significant prevalence of Type 1 allergic reactions, affecting 35-45 million Americans and causing over 500,000 ER visits annually. He defines anaphylaxis as either severe single-system involvement (skin, respiratory, or cardiovascular) or any two-system involvement regardless of severity. This definition aims to encourage earlier treatment with epinephrine rather than waiting until symptoms become life-threatening.
The presentation highlights that while 85% of anaphylaxis cases involve mucocutaneous symptoms and 80% involve respiratory symptoms, there remains a troubling gap in treatment. Even among pediatric patients who receive epinephrine in emergency departments, not all receive this life-saving medication promptly. Dr. Dixit emphasizes that every patient experiencing anaphylaxis should receive immediate epinephrine administration, as delays can result in preventable fatalities.
